Condition
Leukemia, Myelomonocytic, Acute
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Completed2
Unknown1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01174043Phase 2CompletedPrimary
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
NCT04687657Phase 1UnknownPrimary
Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia
NCT02527174Phase 1Withdrawn
A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia
NCT00363974Phase 1CompletedPrimary
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
Showing all 4 trials